Pemphigus. S2 Guideline for diagnosis and treatment - Guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 3, 2015, Pages 405-414

  Hertl, M ^a   Jedlickova, H ^b   Karpati, S ^c   Marinovic, B ^d   Uzun, S ^e   Yayli, S ^f   Mimouni, D ^g   Borradori, L ^h   Feliciani, C ⁱ   Ioannides, D ^j   Joly, P ^k   Kowalewski, C ^l   Zambruno, G ^m   Zillikens, D ⁿ   Jonkman, M F ^o  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b MASARYK UNIVERSITY   (Czech Republic)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF ZAGREB   (Croatia)

^e AKDENIZ UNIVERSITY   (Turkey)

^f KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^g TEL AVIV UNIVERSITY   (Israel)

^h UNIVERSITY OF BERN   (Switzerland)

ⁱ UNIVERSITY OF PARMA   (Italy)

^j ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^k ROUEN UNIVERSITY HOSPITAL   (France)

^l MEDICAL UNIVERSITY OF WARSAW   (Poland)

^m L'Istituto Dermopatico dell'Immacolata ^*  (Italy)

ⁿ UNIVERSITY OF LÜBECK   (Germany)

^o UNIVERSITY OF GRONINGEN   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; RITUXIMAB;

CLINICAL EXAMINATION; CONSENSUS DEVELOPMENT; CONSULTATION; CORTICOSTEROID THERAPY; DERMATOLOGIST; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; HUMAN; IGA PEMPHIGUS; IMMUNOADSORPTION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL HISTORY; MEDICAL SOCIETY; NONHUMAN; OUTCOME ASSESSMENT; PARANEOPLASTIC PEMPHIGUS; PATIENT INFORMATION; PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEROLOGY; SUPPORT GROUP; VACCINATION; EUROPE;

EUROPE; HUMANS; PEMPHIGUS;

EID: 84923063504     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12772     Document Type: Review

References (41)

1. Joly P, Litrowski N,. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011; 29: 432-436.
2. Kneisel A, Hertl M,. Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges 2011; 9: 844-856; quiz 857.
3. Kneisel A, Hertl M,. Autoimmune bullous skin diseases. Part 2: diagnosis and therapy. J Dtsch Dermatol Ges 2011; 9: 927-947.
4. Amagai M, Klaus-Kovtun V, Stanley JR,. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-877.
5. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA,. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-1196.
6. Martin LK, Werth V, Villanueva E, Segall J, Murrell DF,. Interventions for pemphigus vulgaris and pemphigus foliaceus. Cochrane Database Syst Rev 2009; Jan 21;(1): CD006263.
7. Martin LK, Werth VP, Villaneuva EV, Murrell DF,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-908.
8. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ,. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 1059-1062.
9. Joly P, Bernard P, Bedane C, Prost C, Ingen-Housz-Oro S,. Pemphigus. Guidelines for the diagnosis and treatment. Centres de reference des maladies bulleuses auto-immunes. Societe Francaise de Dermatologie. Ann Dermatol Venereol 2011; 138: 252-258.
10. Harman KE, Albert S, Black MM,. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003; 149: 926-937.
11. Poot AM, Diercks GF, Kramer D, et al,. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013; 169: 1016-1024.
12. Thompson AJ, Newman WG, Elliott RA, Roberts SA, Tricker K, Payne K,. The cost-effectiveness of a pharmacogenetic test: a trial-based evaluation of TPMT genotyping for azathioprine. Value Health 2014; 17: 22-33.
13. Mentink LF, Mackenzie MW, Toth GG, et al,. Randomized controlled trial of adjuvant oral dexamethasone pulse therapy in pemphigus vulgaris: PEMPULS trial. Arch Dermatol 2006; 142: 570-576.
14. Toth GG, Westerlaken BO, Eilders M, Laseur M, Jonkman MF, Uges DR,. Dexamethasone pharmacokinetics after high-dose oral therapy for pemphigus. Ann Pharmacother 2002; 36: 1108-1109.
15. Chams-Davatchi C, Mortazavizadeh A, Daneshpazhooh M, et al,. Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris. J Eur Acad Dermatol Venereol 2013; 27 (10): 1285-1292.
16. Beissert S, Werfel T, Frieling U, et al,. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-1454.
17. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ,. Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-2048.
18. Ioannides D, Apalla Z, Lazaridou E, Rigopoulos D,. Evaluation of mycophenolate mofetil as a steroid-sparing agent in pemphigus: a randomized, prospective study. J Eur Acad Dermatol Venereol 2012; 26: 855-860.
19. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al,. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-628.
20. Badalamenti SA, Kerdel FA,. Azathioprine. In: Wolverton SE, ed. Comprehensive Dermatologic Drug Therapy. 2nd ed. London: Elsevier, 2007: 183-195.
21. Meggitt SJ, Anstey AV,. Mohd Mustapa MF, Reynolds NJ, Wakelin S. British Association of Dermatologists' guidelines for the safe and effective prescribing of azathioprine 2011. Br J Dermatol 2011; 165: 711-734.
22. Kasperkiewicz M, Shimanovich I, Meier M, et al,. Treatment of severe pemphigus with a combination of immunoadsorption, rituximab, pulsed dexamethasone and azathioprine/mycophenolate mofetil: a pilot study of 23 patients. Br J Dermatol 2012; 166: 154-160.
23. Ahmed AR, Spigelman Z, Cavacini LA, Posner MR,. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med 2006; 355: 1772-1779.
24. Joly P, Mouquet H, Roujeau JC, et al,. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med 2007; 357: 545-552.
25. Hertl M, Zillikens D, Borradori L, et al,. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges 2008; 6: 366-373.
26. Amagai M, Ikeda S, Shimizu H, et al,. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
27. Zillikens D, Derfler K, Eming R, et al,. Recommendations for the use of immunoapheresis in the treatment of autoimmune bullous diseases. J Dtsch Dermatol Ges 2007; 5: 881-887.
28. Behzad M, Möbs C, Kneisel A, et al,. Combined treatment with immunoadsorption and rituximab leads to fast and prolonged clinical remission in difficult-to-treat pemphigus vulgaris. Br J Dermatol 2012; 166: 844-852.
29. Pasricha JS, Khaitan BK, Raman RS, Chandra M,. Dexamethasone-cyclophosphamide pulse therapy for pemphigus. Int J Dermatol 1995; 34: 875-882.
30. Nousari CH, Brodsky R, Anhalt GJ,. Evaluating the role of immunoablative high-dose cyclophosphamide therapy in pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 148-150.
31. Baum S, Greenberger S, Samuelov L, et al,. Methotrexate is an effective and safe adjuvant therapy for pemphigus vulgaris. Eur J Dermatol 2012; 22: 83-87.
32. Werth VP, Fivenson D, Pandya AG, et al,. Multicenter randomized, double-blind, placebo-controlled, clinical trial of dapsone as a glucocorticoid-sparing agent in maintenance-phase pemphigus vulgaris. Arch Dermatol 2008; 144: 25-32.
33. Iraji F, Asilian A, Siadat AH,. Pimecrolimus 1% cream in the treatment of cutaneous lesions of pemphigus vulgaris: a double-blind, placebo-controlled clinical trial. J Drugs Dermatol 2010; 9: 684-686.
34. Cohen SN, Lim RP, Paul CJ, Abdullah A,. Equal efficacy of topical tacrolimus and clobetasone butyrate in pemphigus foliaceus. Int J Dermatol 2006; 45: 1379.
35. Grossmann JM, Gordon R, Ranganath VK, et al,. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010; 62: 1515-1526.
36. Guslandi M,. Steroid ulcers: any news? World J Gastrointest Pharmacol Ther 2013; 4: 39-40.
37. Murrell DF, Dick S, Ahmed AR, et al,. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
38. Horvath B, Huizinga J, Pas HH, Mulder AB, Jonkman MF,. Low-dose rituximab is effective in pemphigus. Br J Dermatol 2011; 166: 405-412.
39. Kanwar AJ, Vinay K, Sawatkar GU, et al,. Clinical and immunological outcomes of high and low dose rituximab treatments in pemphigus patients: a randomized comparative observer blinded study. Br J Dermatol 2014; 170 (6): 1341-1349.
40. Amber K, Hertl M,. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol. 2014; Sep 3. doi: 10.1111/jdv.12678. [Epub ahead of print].
41. Carbone J,. Adverse reactions and pathogen safety of intravenous immunoglobulin. Curr Drug Saf 2007; 2: 9-18.